Technical Analysis for MIRM - Mirum Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | -3.61% | |
| MACD Bullish Centerline Cross | Bullish | -6.37% | |
| Bollinger Band Squeeze | Range Contraction | -6.37% | |
| Up 3 Days in a Row | Strength | -6.37% | |
| Crossed Above 50 DMA | Bullish | -4.81% | |
| MACD Bullish Signal Line Cross | Bullish | -4.81% |
| Alert | Time |
|---|---|
| Down 1 ATR | 4 days ago |
| Down 3% | 4 days ago |
| 60 Minute Opening Range Breakdown | 4 days ago |
| Fell Below 10 DMA | 4 days ago |
| Down 2 % | 4 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2024
Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It is also developing Volixibat, an investigational oral inhibitor of ASBT, a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company was incorporated in 2018 and is based in Foster City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Acid Recycling Liver Disease Hepatology Progressive Digestive Diseases Liver Bile Acid Primary Biliary Cholangitis Cholestasis Intrahepatic Cholestasis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Acid Recycling Liver Disease Hepatology Progressive Digestive Diseases Liver Bile Acid Primary Biliary Cholangitis Cholestasis Intrahepatic Cholestasis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.56 |
| 52 Week Low | 23.14 |
| Average Volume | 476,136 |
| 200-Day Moving Average | 28.05 |
| 50-Day Moving Average | 25.24 |
| 20-Day Moving Average | 25.30 |
| 10-Day Moving Average | 25.07 |
| Average True Range | 1.07 |
| RSI (14) | 45.05 |
| ADX | 19.11 |
| +DI | 21.28 |
| -DI | 19.15 |
| Chandelier Exit (Long, 3 ATRs) | 23.78 |
| Chandelier Exit (Short, 3 ATRs) | 26.34 |
| Upper Bollinger Bands | 26.48 |
| Lower Bollinger Band | 24.12 |
| Percent B (%b) | 0.18 |
| BandWidth | 9.33 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.05 |
| MACD Histogram | 0.0319 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 26.37 | ||||
| Resistance 3 (R3) | 26.47 | 25.97 | 26.06 | ||
| Resistance 2 (R2) | 25.97 | 25.51 | 25.92 | 25.96 | |
| Resistance 1 (R1) | 25.26 | 25.22 | 25.01 | 25.16 | 25.86 |
| Pivot Point | 24.76 | 24.76 | 24.64 | 24.71 | 24.76 |
| Support 1 (S1) | 24.05 | 24.30 | 23.80 | 23.95 | 23.24 |
| Support 2 (S2) | 23.55 | 24.01 | 23.50 | 23.14 | |
| Support 3 (S3) | 22.84 | 23.55 | 23.04 | ||
| Support 4 (S4) | 22.74 |
